Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients

International Journal of Rheumatic Diseases

Volumn 15, Issue 1, 2012, Pages 25-35

  Higgs, Brandon W ^a   Zhu, Wei ^a   Richman, Laura ^a   Fiorentino, David F ^b   Greenberg, Steven A ^c   Jallal, Bahija ^a   Yao, Yihong ^a  

^a MEDIMMUNE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cytokines; Interferon ; Microarray; Myositis; Rheumatoid arthritis (RA); Systemic lupus erythematosus (SLE); Systemic scleroderma (SSc)

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; MAJOR CLINICAL STUDY; PATHOGENESIS; POLYMYOSITIS; POPULATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; GENE EXPRESSION PROFILING; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE I; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MYOSITIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84857051286     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01654.x     Document Type: Article

References (40)

1. O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol2, 37-45.
2. Feldmann M, Brennan FM, Maini RN (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol14, 397-440.
3. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA295, 2275-85.
4. Stewart TA (2003) Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev14, 139-54.
5. Crow M (2003) Interferon-α: a new target for therapy in systemic lupus erythematosus?Arthritis Rheum48, 2396-401.
6. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol23, 307-36.
7. Ratner M (2009) Human Genome Sciences trial data wow lupus community. Nat Biotechnol27, 779-80.
8. Yao Y, Higgs BW, Morehouse Cet al. (2009) Development of potential pharmacodynamic and diagnostic markers for anti-IFN-α monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics, DOI:. [Cited 31 May 2009]. Available at URL:
9. Yao Y, Richman L, Higgs BW (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum60, 1785-96.
10. Greenberg SA, Higgs BW, Yao Yet al. (2011) Relationship between Disease Activity and Type I Interferon- and Other Cytokine-Inducible Gene Expression in Blood in Dermatomyositis and Polymyositis. Genes and Immunit (forthcoming).
11. Tan E, Cohen A, Fries Jet al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum25, 1271-7.
12. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [Letter]. Arthritis Rheum40, 1725.
13. Arnett FC, Edworthy SM, Luthra HSet al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum31, 315-24.
14. R Development Core Team (2007) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, [Accessed on 2 Dec 2007.] Available from URL:
15. Krzywinski M, Schein J, Birol Iet al. (2009) Circos: an information aesthetic for comparative genomics. Genome Res19, 1639-45.
16. Storey JD (2002) A direct approach to false discovery rates. J Royal Statistical Soc, Series B64, 479-98.
17. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA95, 15623-8. PubMed PMID: 9861020.
18. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis66, 1008-14.
19. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G (2000) Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol99, 585-8.
20. Hengstman G, Van den Housen F, Van Engelen B (2000) Anti-TNF-blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheumatol43, S193.
21. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatol (Oxford)44, 562-3.
22. Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G (2002) Interleukin-13 in autoimmune rheumatic diseases: relationship with the autoantibody profile. Clin Exp Rheumatol20, 213-6.
23. Pittoni V, Bombardieri M, Spinelli FRet al. (2002) Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis61, 723-5.
24. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet29, 244-7.
25. Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F (2010) Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med16, 552-7. Epub 2010 Aug 2. Review.
26. Simon J, Surber R, Kleinstäuber Get al. (2001) Systemic macrophage activation in locally-induced experimental arthritis. J Autoimmun17, 127-36.
27. Pohlers D, Siegling A, Buchner Eet al. (2005) Expression of cytokine mRNA and protein in joints and lymphoid organs during the course of rat antigen-induced arthritis. Arthritis Res Ther7, R445-57.
28. Kim GT, Cho ML, Park YEet al. (2010) Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol29, 273-9.
29. Nakae S, Nambu A, Sudo Ket al. (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol171, 6173-7.
30. Lubberts E, Koenders MI, Oppers-Walgreen Bet al. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum50, 650-9.
31. Plater-Zyberk C, Joosten LA, Helsen MMet al. (2009) Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann Rheum Dis68, 721-8.
32. Hueber AJ, Asquith DL, McInnes IB, Miller AM (2010) Embracing novel cytokines in RA - complexity grows as does opportunity!Best Pract Res Clin Rheumatol24, 479-87.
33. Kurasawa K, Hirose K, Sano Het al. (2000) Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum43, 2455-63.
34. Murata M, Fujimoto M, Matsushita Tet al. (2008) Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?J Dermatol Sci50, 240-2.
35. Katz Y, Nadiv O, Beer Y (2001) Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes. Arthritis Rheum44, 2176-84.
36. Prud'homme GJ (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest87, 1077-91.
37. Asarch A, Barak O, Loo DS, Gottlieb AB (2008) Th17 cells: a new therapeutic target in inflammatory dermatoses. J Dermatolog Treat19, 318-26.
38. Rossi G (1998) Expression of GM-CSF receptor and "in vitro" effects of GM-CSF on human fibroblasts. Life Sci63, 327-36.
39. Postiglione L, Montagnani S, Riccio Aet al. (2002) Enhanced expression of the receptor for granulocyte macrophage colony stimulating factor on dermal fibroblasts from scleroderma patients. J Rheumatol29, 94-101.
40. Lateef A, Petri M (2010) Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol22, 504-9.